When was ImmunoGen founded?

ImmunoGen was founded in 1981 and raised its 1st funding round 30 years after it was founded.

Where is ImmunoGen located?

ImmunoGen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts.

How many employees does ImmunoGen have?

As of Mar 31, 2026, the latest employee count at ImmunoGen is 147.

Is ImmunoGen a funded company?

ImmunoGen is a funded company, having raised a total of $126M across 5 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Jun 15, 2011.

When was the latest funding round of ImmunoGen?

ImmunoGen's latest funding was a $***** PE round on Jun 2016, with participation from 0 investor.

What is the annual revenue of ImmunoGen?

Annual revenue of ImmunoGen is $109M as on Dec 31, 2022.

Where does ImmunoGen rank among its competitors?

ImmunoGen ranks 242nd amongst 3201 active competitors, of which 1095 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of ImmunoGen?

ImmunoGen's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

ImmunoGen - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of antibody drug conjugates for the treatment of cancer. The company develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, Mirvetuximab Soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. The technology is used in Roche’s Kadcyla (ado-trastuzumab emtansine for HER2-positive metastatic breast cancer) and is licensed by other leading healthcare companies.

Website: immunogen.com
Social
Email ID: *****@immunogen.com
Registered Address: Waltham, Massachusetts

Key Metrics

Founded Year

1981

Location

Waltham, United States

Stage

Acquired

Total Funding

$126M in 5 rounds

Latest Funding Round

PE, Jun 2016, $*****

Investors

Transpac & 3 more

Ranked

242^nd among 3201 active competitors

Annual Revenue

$109M as on Dec 31, 2022

Employee Count

147 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3053 more

Exit Details

Acquired by AbbVie (Nov 30, 2023)

View ImmunoGen's full profile

ImmunoGen is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Immunogen, Inc. CIN: 42726691 , United States, Active	Dec 26, 999	$109M (As on Dec 31, 2022)	225 (As on Dec 31, 2024)	-
IMMUNOGEN INC CIN: 855654 , United States, Active	May 23, 2019	$53.4M (As on Dec 31, 2018)	-	-

ImmunoGen got acquired by AbbVie on Nov 30, 2023. It was facilitated by J P Morgan, Morgan Stanley, Wachtell, Lipton, Rosen & Katz and 3 more.

Click here to take a look at ImmunoGen's acquisition in detail

ImmunoGen has raised a total funding of $126M over 5 rounds. Its first funding round was on Jun 15, 2011. ImmunoGen has 4 institutional investors.

Here is the list of recent funding rounds of ImmunoGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 2016	1869010	PE	8274259	9091441	7416791	1659701
Dec 20, 2011	3022391	PE	4420817	7766010	4260720	7071410
Nov 14, 2011	3894268	Angel	5474598	3803226	8114088	1247092

Access funding benchmarks and valuations. Sign up today!

View details of ImmunoGen's funding rounds and investors

ImmunoGen's employee count trend

ImmunoGen has 147 employees as of Mar 26. Here is ImmunoGen's employee count trend over the years:

Uncover ImmunoGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ImmunoGen include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of ImmunoGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
242nd	ImmunoGen 1981, Waltham (United States), Acquired	Developer of antibody drug conjugates for the treatment of cancer	$126M	Transpac, NB Capital & 2 others	59/100